2014年

1. Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects.

   Hosen N, Maeda T, Hashii Y, Tsuboi A, Nishida S, Nakata J, Nakae Y, Takashima S, Oji Y, Oka Y, Kumanogoh A, Sugiyama H

   Expert review of hematology　7(5) 671-681　2014年10月FullTxt

2. The Wilms' Tumor Gene WT1 - 17AA/- KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model.

   Yamanouchi K, Ohta T, Liu Z, Oji Y, Sugiyama H, Shridhar V, Matsumura S, Takahashi T, Takahashi K, Kurachi H

   Translational oncology　7(5) 580-589　2014年10月FullTxt

3. Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma.

   Andersson C, Oji Y, Ohlson N, Wang S, Li X, Ottander U, Lundin E, Sugiyama H, Li A

   Cancer medicine　3(4) 909-918　2014年8月FullTxt

4. In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity.

   Nakata J, Nakano K, Okumura A, Mizutani Y, Kinoshita H, Iwai M, Hasegawa K, Morimoto S, Fujiki F, Tatsumi N, Nakajima H, Nakae Y, Nishida S, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Kumanogoh A, Hosen N

   Leukemia　28(6) 1316-1325　2014年6月FullTxt

5. The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.

   Oji Y, Tatsumi N, Fukuda M, Nakatsuka S, Aoyagi S, Hirata E, Nanchi I, Fujiki F, Nakajima H, Yamamoto Y, Shibata S, Nakamura M, Hasegawa K, Takagi S, Fukuda I, Hoshikawa T, Murakami Y, Mori M, Inoue M, Naka T, Tomonaga T, Shimizu Y, Nakagawa M, Hasegawa J, Nezu R, Inohara H, Izumoto S, Nonomura N, Yoshimine T, Okumura M, Morii E, Maeda H, Nishida S, Hosen N, Tsuboi A, Oka Y, Sugiyama H

   International journal of oncology　44(5) 1461-1469　2014年5月FullTxt

6. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.

   Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K, Tsuboi A, Oka Y, Yanagisawa S, Toyama Y, Ikegami M, Kitagawa T, Eguchi H, Wada H, Nagano H, Nakata J, Nakae Y, Hosen N, Oji Y, Tanaka T, Kawase I, Kumanogoh A, Sakamoto J, Doki Y, Mori M, Ohkusa T, Tajiri H, Sugiyama H

   Journal of immunotherapy (Hagerstown, Md. : 1997)　37(2) 105-114　2014年2月FullTxt

7. Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis.

   Kijima N, Hosen N, Kagawa N, Hashimoto N, Kinoshita M, Oji Y, Sugiyama H, Yoshimine T

   Anticancer research　34(1) 61-67　2014年1月FullTxt

2013年

1. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.

   Miyatake T, Ueda Y, Morimoto A, Enomoto T, Nishida S, Shirakata T, Oka Y, Tsuboi A, Oji Y, Hosen N, Nakatsuka S, Morita S, Sakamoto J, Sugiyama H, Kimura T

   Journal of cancer research and clinical oncology　139(3) 457-463　2013年3月FullTxt

2012年

1. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.

   Tamanaka T, Oka Y, Fujiki F, Tsuboi A, Katsuhara A, Nakajima H, Hosen N, Nishida S, Lin YH, Tachino S, Akatsuka Y, Kuzushima K, Oji Y, Kumanogoh A, Sugiyama H

   Anticancer research　32(12) 5201-5209　2012年12月FullTxt

2. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.

   Chiba Y, Kinoshita M, Okita Y, Tsuboi A, Isohashi K, Kagawa N, Fujimoto Y, Oji Y, Oka Y, Shimosegawa E, Morita S, Hatazawa J, Sugiyama H, Hashimoto N, Yoshimine T

   Journal of neurosurgery　116(4) 835-842　2012年4月FullTxt

3. Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors.

   Morimoto S, Oka Y, Tsuboi A, Tanaka Y, Fujiki F, Nakajima H, Hosen N, Nishida S, Nakata J, Nakae Y, Maruno M, Myoui A, Enomoto T, Izumoto S, Sekimoto M, Kagawa N, Hashimoto N, Yoshimine T, Oji Y, Kumanogoh A, Sugiyama H

   Cancer science　103(3) 408-414　2012年3月FullTxt

4. Vaccination with WT-1 (Wilms' tumor gene-1) peptide and BCG-CWS in melanoma.

   Nishioka M, Tanemura A, Nishida S, Nakano A, Tsuboi A, Oji Y, Oka Y, Azuma I, Sugiyama H, Katayama I

   European journal of dermatology : EJD　22(2) 258-259　2012年3月FullTxt

5. WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.

   Shirakata T, Oka Y, Nishida S, Hosen N, Tsuboi A, Oji Y, Murao A, Tanaka H, Nakatsuka S, Inohara H, Sugiyama H

   Anticancer research　32(3) 1081-1085　2012年3月FullTxt

6. Low Wilms' tumor gene expression in tumor tissues predicts poor prognosis in patients with non-small-cell lung cancer.

   Hayashi S, Oji Y, Kanai Y, Teramoto T, Kitaichi M, Kawaguchi T, Okada M, Sugiyama H, Matsumura A

   Cancer investigation　30(2) 165-171　2012年2月FullTxt

7. CD48 as a novel molecular target for antibody therapy in multiple myeloma.

   Hosen N, Ichihara H, Mugitani A, Aoyama Y, Fukuda Y, Kishida S, Matsuoka Y, Nakajima H, Kawakami M, Yamagami T, Fuji S, Tamaki H, Nakao T, Nishida S, Tsuboi A, Iida S, Hino M, Oka Y, Oji Y, Sugiyama H

   British journal of haematology　156(2) 213-224　2012年1月FullTxt

8. Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.

   Nakajima H, Oka Y, Tsuboi A, Tatsumi N, Yamamoto Y, Fujiki F, Li Z, Murao A, Morimoto S, Hosen N, Shirakata T, Nishida S, Kawase I, Isaka Y, Oji Y, Sugiyama H

   Vaccine　30(4) 722-729　2012年1月FullTxt

2011年

1. Expression of Wilms tumor 1 gene in a variety of pediatric tumors.

   Oue T, Uehara S, Yamanaka H, Takama Y, Oji Y, Fukuzawa M

   Journal of pediatric surgery　46(12) 2233-2238　2011年12月FullTxt

2. The role of WT1 gene in neuroblastoma.

   Wang J, Oue T, Uehara S, Yamanaka H, Oji Y, Fukuzawa M

   Journal of pediatric surgery　46(2) 326-331　2011年2月FullTxt

2010年

1. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient.

   Oji Y, Oka Y, Nishida S, Tsuboi A, Kawakami M, Shirakata T, Takahashi K, Murao A, Nakajima H, Narita M, Takahashi M, Morita S, Sakamoto J, Tanaka T, Kawase I, Hosen N, Sugiyama H

   European journal of haematology　85(4) 358-360　2010年10月FullTxt

2. Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes.

   Tamura H, Dan K, Yokose N, Iwakiri R, Ohta M, Sakamaki H, Tohyama K, Kondo A, Hyodo H, Nakamura K, Yamashita T, Elisseeva OA, Oka Y, Oji Y, Sugiyama H, Ogata K

   Leukemia research　34(8) 986-990　2010年8月FullTxt

3. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.

   Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, Stein B, Smits EL, Schroyens WA, Gadisseur AP, Vrelust I, Jorens PG, Goossens H, de Vries IJ, Price DA, Oji Y, Oka Y, Sugiyama H, Berneman ZN

   Proceedings of the National Academy of Sciences of the United States of America　107(31) 13824-13829　2010年8月FullTxt

4. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.

   Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Tanaka-Harada Y, Hosen N, Nishida S, Shirakata T, Nakajima H, Tatsumi N, Hashimoto N, Taguchi T, Ueda S, Nonomura N, Takeda Y, Ito T, Myoui A, Izumoto S, Maruno M, Yoshimine T, Noguchi S, Okuyama A, Kawase I, Oji Y, Sugiyama H

   Anticancer research　30(6) 2247-2254　2010年6月FullTxt

5. Sensitive immunohistochemical detection of WT1 protein in tumors with anti-WT1 antibody against WT1 235 peptide.

   Ichinohasama R, Oji Y, Yokoyama H, Takeuchi K, Fujiwara T, Ishizawa K, Taniguchi O, Tsuboi A, Oka Y, Sugiyama H

   Cancer science　101(5) 1089-1092　2010年5月FullTxt

6. High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ.

   Murao A, Oka Y, Tsuboi A, Elisseeva OA, Tanaka-Harada Y, Fujiki F, Nakajima H, Nishida S, Hosen N, Shirakata T, Hashimoto N, Myoui A, Ueda T, Takeda Y, Osaki T, Enomoto T, Yoshikawa H, Kimura T, Oji Y, Kawase I, Sugiyama H

   Cancer science　101(4) 848-854　2010年4月FullTxt

7. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.

   Tanaka-Harada Y, Kawakami M, Oka Y, Tsuboi A, Katagiri T, Elisseeva OA, Nishida S, Shirakata T, Hosen N, Fujiki F, Murao A, Nakajima H, Oji Y, Kanda Y, Kawase I, Sugiyama H

   Cancer science　101(3) 594-600　2010年3月FullTxt

2009年

1. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor.

   Oji Y, Kitamura Y, Kamino E, Kitano A, Sawabata N, Inoue M, Mori M, Nakatsuka S, Sakaguchi N, Miyazaki K, Nakamura M, Fukuda I, Nakamura J, Tatsumi N, Takakuwa T, Nishida S, Shirakata T, Hosen N, Tsuboi A, Nezu R, Maeda H, Oka Y, Kawase I, Aozasa K, Okumura M, Miyoshi S, Sugiyama H

   International journal of cancer　125(2) 381-387　2009年7月FullTxt

2. Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle.

   Nakamura J, Aoyagi S, Nanchi I, Nakatsuka S, Hirata E, Shibata S, Fukuda M, Yamamoto Y, Fukuda I, Tatsumi N, Ueda T, Fujiki F, Nomura M, Nishida S, Shirakata T, Hosen N, Tsuboi A, Oka Y, Nezu R, Mori M, Doki Y, Aozasa K, Sugiyama H, Oji Y

   International journal of oncology　34(5) 1181-1189　2009年5月FullTxt

3. WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.

   Ohta H, Hashii Y, Yoneda A, Takizawa S, Kusuki S, Tokimasa S, Fukuzawa M, Tsuboi A, Murao A, Oka Y, Oji Y, Aozasa K, Nakatsuka S, Sugiyama H, Ozono K

   Pediatric hematology and oncology　26(1) 74-83　2009年1月FullTxt

2008年

1. A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells.

   Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA, Harada Y, Li Z, Tatsumi N, Kamino E, Shirakata T, Nishida S, Taniguchi Y, Kawase I, Oji Y, Sugiyama H

   Microbiology and immunology　52(12) 591-600　2008年12月FullTxt

2. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.

   Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H, Yoshimine T

   Journal of neurosurgery　108(5) 963-971　2008年5月FullTxt

3. Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors.

   Tatsumi N, Oji Y, Tsuji N, Tsuda A, Higashio M, Aoyagi S, Fukuda I, Ito K, Nakamura J, Takashima S, Kitamura Y, Miyai S, Jomgeow T, Li Z, Shirakata T, Nishida S, Tsuboi A, Oka Y, Sugiyama H

   International journal of oncology　32(3) 701-711　2008年3月FullTxt

2007年

1. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.

   Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S, Hosen N, Ogata A, Kito K, Fujiki F, Nishida S, Shirakata T, Ohno S, Yasukawa M, Oji Y, Kawakami M, Morita S, Sakamoto J, Udaka K, Kawase I, Sugiyama H

   International journal of hematology　86(5) 414-417　2007年12月FullTxt

2. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.

   Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, Krensky AM, Weissman IL

   Proceedings of the National Academy of Sciences of the United States of America　104(26) 11008-11013　2007年6月FullTxt

3. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.

   Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H

   Journal of immunotherapy (Hagerstown, Md. : 1997)　30(3) 282-293　2007年4月FullTxt

2006年

1. Immunohistochemical detection of WT1 protein in a variety of cancer cells.

   Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K

   Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc　19(6) 804-814　2006年6月FullTxt

2. Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma.

   Sotobori T, Ueda T, Oji Y, Naka N, Araki N, Myoui A, Sugiyama H, Yoshikawa H

   Cancer　106(10) 2233-2240　2006年5月FullTxt

3. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.

   Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H, Sakamoto J

   Japanese journal of clinical oncology　36(4) 231-236　2006年4月FullTxt

4. Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro.

   Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A, Nakazawa T, Tatsumi N, Sakaguchi N, Takashima S, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Itoh K, Sugiyama H

   Cancer science　97(4) 259-270　2006年4月FullTxt

2005年

1. The Wilms' tumor gene WT1 is a common marker of progenitor cells in fetal liver.

   Kanato K, Hosen N, Yanagihara M, Nakagata N, Shirakata T, Nakazawa T, Nishida S, Tsuboi A, Kawakami M, Masuda T, Oka Y, Oji Y, Ijpenberg A, Hastie ND, Sugiyama H

   Biochemical and biophysical research communications　326(4) 836-843　2005年1月FullTxt

2004年

1. Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors.

   Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, Abeno S, Tatsumi N, Yokota A, Aoyagi S, Nakazawa T, Ito K, Kanato K, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Aozasa K, Yoshimine T, Sugiyama H

   Cancer science　95(10) 822-827　2004年10月FullTxt

2. Overexpression of the Wilms' tumor gene WT1 in esophageal cancer.

   Oji Y, Yano M, Nakano Y, Abeno S, Nakatsuka S, Ikeba A, Yasuda T, Fujiwara Y, Takiguchi S, Yamamoto H, Fujita S, Kanato K, Ito K, Jomgeow T, Kawakami M, Tsuboi A, Shirakata T, Nishida S, Hosen N, Oka Y, Aozasa K, Monden M, Sugiyama H

   Anticancer research　24(5B) 3103-3108　2004年9月FullTxt

3. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.

   Nakajima H, Kawasaki K, Oka Y, Tsuboi A, Kawakami M, Ikegame K, Hoshida Y, Fujiki F, Nakano A, Masuda T, Wu F, Taniguchi Y, Yoshihara S, Elisseeva OA, Oji Y, Ogawa H, Azuma I, Kawase I, Aozasa K, Sugiyama H

   Cancer immunology, immunotherapy : CII　53(7) 617-624　2004年7月FullTxt

4. Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma.

   Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N, Abeno S, Ikeba A, Takashima S, Tsujie M, Yamamoto H, Sakon M, Nezu R, Kawano K, Nishida S, Ikegame K, Kawakami M, Tsuboi A, Oka Y, Yoshikawa K, Aozasa K, Monden M, Sugiyama H

   Cancer science　95(7) 583-587　2004年7月FullTxt

5. Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer.

   Oji Y, Miyoshi Y, Kiyotoh E, Koga S, Nakano Y, Ando A, Hosen N, Tsuboi A, Kawakami M, Ikegame K, Oka Y, Ogawa H, Noguchi S, Sugiyama H

   Japanese journal of clinical oncology　34(2) 74-77　2004年2月FullTxt

6. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.

   Tsuboi A, Oka Y, Osaki T, Kumagai T, Tachibana I, Hayashi S, Murakami M, Nakajima H, Elisseeva OA, Fei W, Masuda T, Yasukawa M, Oji Y, Kawakami M, Hosen N, Ikegame K, Yoshihara S, Udaka K, Nakatsuka S, Aozasa K, Kawase I, Sugiyama H

   Microbiology and immunology　48(3) 175-184　2004年FullTxt

2003年

1. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.

   Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, Elisseeva OA, Masuda T, Nakano A, Kawakami M, Oji Y, Ikegame K, Hosen N, Udaka K, Yasukawa M, Ogawa H, Kawase I, Sugiyama H

   International journal of hematology　78(1) 56-61　2003年7月

2. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia.

   Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Nishida S, Oji Y, Oka Y, Sugiyama H

   Blood　101(5) 1698-1704　2003年3月FullTxt

2002年

1. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.

   Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I, Sugiyama H

   Cancer immunology, immunotherapy : CII　51(11-12) 614-620　2002年12月FullTxt

2. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies.

   Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH, Soma T, Tamaki H, Kawakami M, Oji Y, Hosen N, Kubota T, Nakagawa M, Yamagami T, Hiraoka A, Tsukaguchi M, Udaka K, Ogawa H, Kishimoto T, Nomura T, Sugiyama H

   Blood　99(9) 3272-3279　2002年5月FullTxt

3. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells.

   Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, Kawakami M, Asada M, Kanato K, Motomura M, Murakami M, Fujioka T, Masuda T, Kim EH, Tsuboi A, Oka Y, Soma T, Ogawa H, Sugiyama H

   British journal of haematology　116(2) 409-420　2002年2月FullTxt